AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting

AngioDynamics Inc. (NASDAQ: ANGO) on Tuesday posted a fourth-quarter 2025 adjusted loss of 3 cents per share, compared to the consensus for a per-share loss of 12 cents.

Vascular system-focused medical device maker reported sales of $80.2 million, up 12.7% year over year, beating the consensus of $74.26 million.

The report also revealed:

Med Tech net sales were $35.8 million, a 22% increase from $29.3 million in the prior-year period.

Growth was driven by Auryon sales during the quarter of $15.6 million, which increased 19.7%.

Mechanical Thrombectomy revenue, which includes AngioVac and AlphaVac, of $11.3 million, an increase of 44.7%.

NanoKnife disposable sales of $5.7 million, which increased 5.5% compared to the fourth quarter of fiscal ...